BMS Buys IFM Therapeutics for Cancer Pipeline

Aug 06, 2017

Bristol-Myers Squibb announced the acquisition of IFM Therapeutics, a startup biotech focused on developing therapies that modulate novel targets in the immune system to treat cancer, autoimmunity and inflammatory disorders.

BMS will buy the privately held IFM for an upfront payment of $300 million, gaining access to the company's preclinical cancer programs.

Specifically, the acquisition will give BMS full rights to IFM’s preclinical STING (stimulator of interferon genes) and NLRP3 agonist programs focused on enhancing the innate immune response for treating cancer.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments